ArticleIs it possible to reduce the incidence of weekend oocyte retrievals in GnRH antagonist protocols?
Introduction
Recombinant FSH/gonadotrophin-releasing hormone (GnRH) antagonist regimens have been shown to be safe and effective for women undergoing ovarian stimulation for IVF and intracytoplasmic sperm injection (ICSI). Two pivotal trials, using follitropin beta injection in combination with the GnRH antagonist ganirelix acetate, have demonstrated high ongoing pregnancy rates: 45% in an open-label, non-controlled multicentre trial of 60 IVF patients (Pang et al., 2003) and 38.1% for 750 subjects in the active-control arm of a recent double-blind, randomized, comparator-controlled, multicentre trial (Engage; Devroey et al., 2009).
A recombinant FSH/GnRH antagonist protocol has several advantages for physicians and patients. Compared with GnRH agonist long luteal down-regulation protocols, GnRH antagonist stimulation protocols result in a reduced duration of stimulation, with a lower total dose of recombinant FSH needed to reach the same criterion for human chorionic gonadotrophin (HCG) administration (Tarlatzis et al., 2006). Moreover, the treatment regimen is simpler for the patient, and the reduced number of injections required may reduce the burden of infertility treatment, encourage lower drop-out rates and improve patient compliance (Verberg et al., 2008). With regard to safety, GnRH antagonist regimens are associated with a highly significant reduction in incidence of ovarian hyperstimulation syndrome compared with the GnRH agonist long protocol (Al-Inany et al., 2011).
In some IVF units, there is a desire to avoid oocyte retrieval on weekends. Many assisted reproduction centres now use oral contraceptives as a means to schedule ovarian stimulation cycles in women stimulated with recombinant FSH and a GnRH antagonist; ovarian stimulation can be started during a 2–5-day interval after withdrawal of the oral contraceptive. Comparable ongoing pregnancy rates were achieved in a GnRH antagonist and GnRH agonist protocol using oral contraceptives before treatment (Garcia-Velasco et al., 2011). However, it has been shown that pretreatment with an oral contraceptive in GnRH antagonist protocols, besides complicating the treatment protocol, is associated with a decreased probability of ongoing pregnancy in the fresh transfer cycle (Griesinger et al., 2010). Thus, providing a means for cycle scheduling without pretreatment with an oral contraceptive would improve the patient-centred protocol while maintaining its simplicity.
Previous studies have shown that in recombinant FSH/GnRH agonist protocols, scheduling the starting day of ovarian stimulation was a useful method to avoid oocyte retrieval on weekends, reducing the amount of overtime worked, decreasing cost and inconvenience without compromising IVF outcome (Ben-Chetrit et al., 1997, Nakagawa et al., 1997). In addition, a recent retrospective analysis indicated that simple advancement or delay of HCG administration in a GnRH antagonist protocol may allow clinicians to avoid weekend oocyte retrieval without adversely affecting live birth rates (Tremellen and Lane, 2010). Therefore, the primary objective of the current retrospective analysis was to assess whether adjusting the starting day of ovarian stimulation based on the weekday of start of menses, if necessary combined with delaying the triggering of final oocyte maturation with HCG, could minimize the occurrence of oocyte retrieval during weekends in a recombinant FSH/GnRH antagonist regimen.
Section snippets
Study design
This study conducted a retrospective analysis of data from the reference arm (recombinant FSH/GnRH antagonist) of the Engage trial (Devroey et al., 2009), a multicentre, randomized, double-blind, double-dummy, active-controlled, non-inferiority clinical trial involving women undergoing ovarian stimulation for IVF. The study was conducted in 34 centres (14 in North America, 20 in Europe) between June 2006 and January 2008. The study was conducted in accordance with principles of good clinical
Subjects
Thirty-four centres in North America and Europe recruited subjects into the study. In total, 750 subjects were randomized and treated in the 200-IU recombinant FSH group (Figure 1). Of these, 745 were included in the analysis comparing starting day 2 (n = 364) and 3 (n = 381), since five subjects started on a different day. In total, 739 subjects reached the HCG criterion and 741 subjects actually received HCG, of which 725 received it on the day of reaching the criterion (n = 524) or the day
Acknowledgements
Financial support for this study was provided by Merck Sharp & Dohme Corp. Medical writing and editorial assistance was provided by Katherine Ayling-Rouse, MSc, of PAREXEL, UK, funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA.
References (22)
- et al.
Factors affecting success rates in two concurrent clinical IVF trials: an examination of potential explanations for the difference in pregnancy rates between the United States and Europe
Fertil. Steril.
(2010) - et al.
Oestradiol valerate pretreatment in GnRH-antagonist cycles: a randomized controlled trial
Reprod. Biomed. Online
(2012) - et al.
A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormone
Fertil. Steril.
(2012) - et al.
No detrimental effects in delaying initiation of gonadotropin administration after pituitary desensitization with gonadotropin-releasing hormone agonist
Fertil. Steril.
(1993) - et al.
Programming in vitro fertilization for a 5- or 3-day week
Fertil. Steril.
(1991) - et al.
Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial
Fertil. Steril.
(2011) - et al.
Can oestradiol pretreatment be used to reliably avoid weekend oocyte retrievals?
Reprod. Biomed. Online
(2012) - et al.
Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis
Fertil. Steril.
(2010) - et al.
Efficiency of antagonist IVF cycle programming by estrogens
Gynecol. Obstet. Fertil.
(2010) - et al.
Avoidance of oocyte retrieval on the weekend through the use of scheduled ovarian hyperstimulation for in vitro fertilization and embryo transfer
Fertil. Steril.
(1997)
Administration of recombinant human FSH (solution in cartridge) with a pen device in women undergoing ovarian stimulation
Reprod. Biomed. Online
Cited by (16)
The GnRH antagonist protocol
2023, Handbook of Current and Novel Protocols for the Treatment of InfertilityA machine learning algorithm can optimize the day of trigger to improve in vitro fertilization outcomes
2021, Fertility and SterilityCitation Excerpt :In addition, they found that patients in the late-hCG group had more mature follicles than patients in the early-hCG group, but again, had similar laboratory outcomes and pregnancy rates (19). Prior retrospective studies evaluating whether delaying hCG trigger administration to avoid weekend oocyte retrievals had an impact on outcomes had similar findings (20–23). These studies were not adequately powered to detect differences in pregnancy or live birth rates, and they did not report whether there was an increased risk of complications in either group.
GnRH-antagonist programming versus GnRH agonist protocol: A randomized trial
2015, European Journal of Obstetrics and Gynecology and Reproductive BiologyCitation Excerpt :The intention to create a workweek-based retrieval after steroid exposure has been previously discussed in the literature, though to the best of our knowledge, follicular estrogen was usually not tested. A recent retrospective analysis of GnRH antagonist cycles reported that weekend retrievals can be minimized by selecting the appropriate cycle day to initiate ovarian stimulation and if necessary in combination with a 1-day HCG delay [14]. Hormonal based manipulations for the purpose of postponing retrieval day were reported in orthodox Jewish couples because they refrain from sexual intercourse on the days following vaginal bleeding.
Changing ovarian stimulation parameters in a subsequent cycle does not increase the number of euploid embryos
2015, Fertility and SterilityGONADOTROPIN-RELEASING HORMONE ANTAGONISTS IN OVARIAN STIMULATION FOR IN VITRO FERTILIZATION
2023, Textbook of Assisted Reproductive Techniques: Volume 2: Clinical Perspectives, Sixth Edition
Keith Gordon, PhD, is a regional director in medical affairs for women’s health at Merck. He received his doctoral degree from Monash University, Melbourne, Australia and his training in reproductive endocrinology at The Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, VA, USA. Before joining Merck, he specialized in preclinical modelling of woman’s health conditions. He is a long-standing member of the American Society for Reproductive Medicine and European Society for Human Reproduction and Embryology. He also is the author/co-author of more than 50 peer-reviewed articles and has presented more than 100 abstracts at national/international meetings.
- 1
On behalf of the Engage investigators.